Clinical trials: Type 2 Diabetes (T2D)
Type 2 Diabetes Patients
A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin
This is a randomized, double-blind, placebo-controlled, repeat-dose study to evaluate the safety, tolerability, PK, and PD of L47 as an add-on treatment to stable metformin therapy in patients with T2DM.
- Trial name
- NCT04662164
- Testing
- hepalatide
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes
This trial is conducted in Africa. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart plus OAD compared to biphasic insulin aspart alone on blood glucose control in type 2 diabetes.
- Trial name
- NCT00624364
- Testing
- biphasic insulin aspart, metformin
- Where
- 15 sites in South Africa
- Volunteers
- 140 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients
The aim of this study is to evaluate the efficacy and safety fo CJ-30001/CJ-30002.
- Trial name
- NCT01370707
- Testing
- Metformin, CJ-30001/CJ-30002
- Where
- 21 sites in South Korea
- Volunteers
- 187 people
- Sponsor
- HK inno.N Corporation
Diabetes Type 2, Hyperglycaemia (Diabetic)
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance.
- Conditions
- Diabetes Type 2, Hyperglycaemia (Diabetic), QT Interval, Variation in, Torsades de Pointes
- Trial name
- NCT07014735
- Testing
- glucose, moxifloxacin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Richmond Pharmacology Limited
Diabetes Mellitus, Type 2
To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is designed as a multicenter, randomized, double-blind, parallel-group, placebo-controlled study…
- Trial name
- NCT00325117
- Testing
- Vildagliptin
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin.
- Trial name
- NCT02489968
- Testing
- empagliflozin 10 mg + linagliptin 5 mg, empagliflozin 10 mg, empagliflozin 25 mg + linagliptin 5 mg
- Where
- 83 sites in Japan
- Volunteers
- 880 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin
This is the phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and long-term safety of SAL067 in T2DM patients uncontrolled by metformin, comprising 24 weeks of double-blind treatment…
- Trial name
- NCT05801627
- Testing
- SAL067
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Diabetic Peripheral Neuropathy
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
To evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the neuropathic pain associated with Diabetic Peripheral Neuropathy.
- Trial name
- DPN (NCT03219320)
- Testing
- NYX-2925
- Where
- 35 sites in United States
- Volunteers
- 301 people
- Sponsor
- Aptinyx
Type 2 Diabetes Mellitus
Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus
This observational study is designed to assess the effects of Envlo Tablet or Envlomet SR Tablet on weight loss and safety in patients with Type 2 diabetes, conducted in real primary care settings over a period of 24 weeks.
- Trial name
- NCT06427083
- Testing
- Envlo Tablet, Envolomet SR Tablet
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control…
- Trial name
- NCT01106651
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s)
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 716 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
This trial is designed to show the effect of treatment with TT223 or placebo on blood glucose control after 12 weeks of treatment with a 6 month follow-up.
- Trial name
- NCT00743002
- Testing
- TT223 with Metformin and/or TZD
- Where
- 20 sites in United States
- Volunteers
- 87 people
- Sponsor
- OPKO Health, Inc.
Type 2 Diabetes
A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)
A single dose, open label study to characterize the routes of elimination and determine the mass balance of MK-0941. A single 40 mg dose of MK-0941 will be given orally to male participants with type 2 diabetes.
- Trial name
- NCT00912002
- Testing
- MK-0941
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Coronary Syndrome, Type 2 Diabetes
A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)
The purpose of this study is to determine the safety and feasibility of BXT-51072 as a cardioprotective agent in diabetics undergoing elective angioplasty / percutaneous intervention (PCI), a procedure to "open" coronary…
- Trial name
- NCT00320502
- Testing
- BXT-51072
- Where
- 4 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Synvista Therapeutics, Inc
Diabetes, Diabetes Mellitus, Type 1
Changing Diabetes® World Tour
This study is conducted in the Middle East, Northern Africa and Europe. The aim of this study is to contribute to the design of a simple screening strategy for countries in scope, by exploring the association between risk factors…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01437072
- Testing
- No treatment given
- Where
- 3 sites in Portugal, Saudi Arabia and 1 more
- Volunteers
- 8,304 people
- Sponsor
- Novo Nordisk A/S
Diabete Mellitus, Diabete Type 2
A Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 2 Diabetes Mellitus
This Phase I clinical trial is a multi-center, single-arm, open-label study aimed at evaluating the safety and efficacy of RGB-5088 islet cell infusion in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT07794254
- Testing
- RGB-5088
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Reprogenix Bioscience, Inc
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking…
- Trial name
- NCT00528372
- Testing
- Dapagliflozin, Metformin
- Where
- 78 sites in United States, Canada and 2 more
- Volunteers
- 1,067 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
In this integrated, Phase I study, the safety, tolerability, food effect, and pharmacokinetic (PK) properties of Fixed-Dose Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR and Dapagliflozin / Metformin XR…
- Trial name
- NCT03138356
- Testing
- 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet, 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet, 5 mg dapagliflozin / 850 mg metformin XR FDC
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
The aim of this study is to assess the safety and effectiveness of Ozempic initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions.
- Trial name
- NCT05689372
- Testing
- Semaglutide
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Novo Nordisk A/S
Xerosis Cutis
Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products
The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and…
- Trial name
- NCT05046015
- Testing
- 10% Urea foot lotion, 10% Urea foot ointment
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Galderma R&D
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
- Conditions
- Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes
- Trial name
- TREASURE-CKD (NCT05536804)
- Testing
- Tirzepatide
- Where
- 27 sites in United States, Austria and 4 more
- Volunteers
- 134 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.